Integrating bulk and single-cell sequencing data to construct a Scissor+ dendritic cells prognostic model for predicting prognosis and immune responses in ESCC
View abstract on PubMed
Summary
This summary is machine-generated.Dendritic cells (DCs) in esophageal squamous cell carcinoma (ESCC) vary significantly. Identifying DC subtypes using single-cell RNA sequencing aids in developing prognostic models and targeted therapies for ESCC patients.
Area Of Science
- Oncology
- Immunology
- Genomics
Background
- Esophageal squamous cell carcinoma (ESCC) exhibits molecular heterogeneity impacting treatment response.
- Dendritic cells (DCs) are crucial immune cells influencing cancer prognosis and survival.
- Understanding DC heterogeneity in ESCC is vital for personalized treatment strategies.
Purpose Of The Study
- To dissect the dendritic cell landscape within the ESCC tumor microenvironment using high-resolution single-cell analysis.
- To identify and characterize distinct dendritic cell subpopulations in ESCC patients.
- To develop and validate a prognostic risk model for ESCC based on dendritic cell subtypes.
Main Methods
- Integrated analysis of 192,078 single cells from 60 ESCC patients, including 4,379 dendritic cells.
- Utilized the Scissor method to stratify dendritic cells into Scissor-high (hi) and Scissor-low (low) subtypes based on genomic and clinical associations.
- Applied Scissor-hi gene signature for patient stratification and identified key ligand-receptor interactions.
Main Results
- Dendritic cells were successfully stratified into Scissor-hi and Scissor-low subtypes.
- Scissor-hi patients exhibited significant ligand-receptor mediated cell interactions involving PD-L1, TIGIT, PVR, and IL6.
- A validated prognostic risk model for ESCC was developed based on Scissor findings.
Conclusions
- Dendritic cell subtypes play a critical role in ESCC heterogeneity and patient prognosis.
- Specific gene signatures and cell interactions (PD-L1, TIGIT, PVR, IL6) are associated with the Scissor-hi subtype.
- The developed risk model offers a reliable tool for ESCC prognosis and may guide personalized therapeutic development.

